176 related articles for article (PubMed ID: 37869138)
1. Treatment of stroke in aged male and female rats with Vepoloxamer and tPA reduces neurovascular damage.
Zhang L; Luo H; Li C; Teng H; Powell B; Lu M; Chopp M; Zhang ZG
Front Neurol; 2023; 14():1282736. PubMed ID: 37869138
[TBL] [Abstract][Full Text] [Related]
2. Vepoloxamer Enhances Fibrinolysis of tPA (Tissue-Type Plasminogen Activator) on Acute Ischemic Stroke.
Wang C; Huang R; Li C; Lu M; Emanuele M; Zhang ZG; Chopp M; Zhang L
Stroke; 2019 Dec; 50(12):3600-3608. PubMed ID: 31587657
[TBL] [Abstract][Full Text] [Related]
3. N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Augments Thrombolysis of tPA (Tissue-Type Plasminogen Activator) in Aged Rats After Stroke.
Li C; Zhang L; Wang C; Teng H; Fan B; Chopp M; Zhang ZG
Stroke; 2019 Sep; 50(9):2547-2554. PubMed ID: 31387512
[TBL] [Abstract][Full Text] [Related]
4. Combination treatment with low-dose Niaspan and tissue plasminogen activator provides neuroprotection after embolic stroke in rats.
Shehadah A; Chen J; Cui Y; Zhang L; Roberts C; Lu M; Chopp M
J Neurol Sci; 2011 Oct; 309(1-2):96-101. PubMed ID: 21802695
[TBL] [Abstract][Full Text] [Related]
5. Synthetic, organic compound vepoloxamer (P-188) potentiates tissue plasminogen activator.
Dansdill D; Halandras PM; Beverly J; Jeske W; Hoppensteadt D; Emanuele M; Fareed J; Cho JS
J Vasc Surg; 2018 Jan; 67(1):294-299. PubMed ID: 27939143
[TBL] [Abstract][Full Text] [Related]
6. Opening the window: Ischemic postconditioning reduces the hyperemic response of delayed tissue plasminogen activator and extends its therapeutic time window in an embolic stroke model.
Esmaeeli-Nadimi A; Kennedy D; Allahtavakoli M
Eur J Pharmacol; 2015 Oct; 764():55-62. PubMed ID: 26123846
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke.
Zhang L; Zhang ZG; Zhang R; Morris D; Lu M; Coller BS; Chopp M
Circulation; 2003 Jun; 107(22):2837-43. PubMed ID: 12756151
[TBL] [Abstract][Full Text] [Related]
8. Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats.
Zhang L; Chopp M; Jia L; Cui Y; Lu M; Zhang ZG
J Cereb Blood Flow Metab; 2009 Nov; 29(11):1816-24. PubMed ID: 19638998
[TBL] [Abstract][Full Text] [Related]
9. Transient brain hypothermia reduces the reperfusion injury of delayed tissue plasminogen activator and extends its therapeutic time window in a focal embolic stroke model.
Zarisfi M; Allahtavakoli F; Hassanipour M; Khaksari M; Rezazadeh H; Allahtavakoli M; Taghavi MM
Brain Res Bull; 2017 Sep; 134():85-90. PubMed ID: 28710023
[TBL] [Abstract][Full Text] [Related]
10. Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model.
Zhang L; Zhang ZG; Zhang C; Zhang RL; Chopp M
Stroke; 2004 Dec; 35(12):2890-5. PubMed ID: 15514182
[TBL] [Abstract][Full Text] [Related]
11. Taurine Reduces tPA (Tissue-Type Plasminogen Activator)-Induced Hemorrhage and Microvascular Thrombosis After Embolic Stroke in Rat.
Jin R; Xiao AY; Liu S; Wang M; Li G
Stroke; 2018 Jul; 49(7):1708-1718. PubMed ID: 29844028
[TBL] [Abstract][Full Text] [Related]
12. Postischemic intracarotid treatment with TNK-tPA reduces infarct volume and improves neurological deficits in embolic stroke in the unanesthetized rat.
Zhang RL; Zhang L; Jiang Q; Zhang ZG; Goussev A; Chopp M
Brain Res; 2000 Sep; 878(1-2):64-71. PubMed ID: 10996136
[TBL] [Abstract][Full Text] [Related]
13. Combination treatment with VELCADE and low-dose tissue plasminogen activator provides potent neuroprotection in aged rats after embolic focal ischemia.
Zhang L; Zhang ZG; Buller B; Jiang J; Jiang Y; Zhao D; Liu X; Morris D; Chopp M
Stroke; 2010 May; 41(5):1001-7. PubMed ID: 20203318
[TBL] [Abstract][Full Text] [Related]
14. Whole body hypothermia extends tissue plasminogen activator treatment window in the rat model of embolic stroke.
Hassanipour M; Zarisfi M; Ehsani V; Allahtavakoli M
Life Sci; 2020 Sep; 256():117450. PubMed ID: 32087233
[TBL] [Abstract][Full Text] [Related]
15. Diabetes Worsens Functional Outcomes in Young Female Rats: Comparison of Stroke Models, Tissue Plasminogen Activator Effects, and Sexes.
Li W; Ward R; Valenzuela JP; Dong G; Fagan SC; Ergul A
Transl Stroke Res; 2017 Mar; ():. PubMed ID: 28247188
[TBL] [Abstract][Full Text] [Related]
16. PI3Kγ (Phosphoinositide 3-Kinase-γ) Inhibition Attenuates Tissue-Type Plasminogen Activator-Induced Brain Hemorrhage and Improves Microvascular Patency After Embolic Stroke.
Jin R; Xiao AY; Li J; Wang M; Li G
Hypertension; 2019 Jan; 73(1):206-216. PubMed ID: 30571560
[TBL] [Abstract][Full Text] [Related]
17. MRI evaluation of BBB disruption after adjuvant AcSDKP treatment of stroke with tPA in rat.
Ding G; Zhang Z; Chopp M; Li L; Zhang L; Li Q; Wei M; Jiang Q
Neuroscience; 2014 Jun; 271():1-8. PubMed ID: 24769225
[TBL] [Abstract][Full Text] [Related]
18. An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents.
Wang Y; Zhang Z; Chow N; Davis TP; Griffin JH; Chopp M; Zlokovic BV
Stroke; 2012 Sep; 43(9):2444-9. PubMed ID: 22811462
[TBL] [Abstract][Full Text] [Related]
19. Effects of ML351 and tissue plasminogen activator combination therapy in a rat model of focal embolic stroke.
Cheng G; Zhao W; Xin Y; Huang G; Liu Y; Li Z; Zhan M; Li Y; Lu L; van Leyen K; Liu Y
J Neurochem; 2021 May; 157(3):586-598. PubMed ID: 33481248
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke.
Zhang Z; Zhang L; Yepes M; Jiang Q; Li Q; Arniego P; Coleman TA; Lawrence DA; Chopp M
Circulation; 2002 Aug; 106(6):740-5. PubMed ID: 12163437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
